Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study.

Abstract

Sarcoidosis is a systemic disease of an unknown aetiology, in which non-caseating granulomas are formed in one or multiple organs, with pulmonary involvement in >90% of the sarcoidosis patients [1]. Pulmonary hypertension (PH), defined as a mean pulmonary artery pressure of at least 25 mmHg by right heart catheterisation (RHC) [2] is a well-recognised complication of sarcoidosis, associated with significant increase in mortality [3, 4]. Even though the first case of PH in sarcoidosis was described in 1949 [5], the exact prevalence remains unclear. Only three studies have previously investigated the PH prevalence independently of suggestive symptoms and signs for PH, resulting in prevalence rates of 5.7% and 20.8% [6–8]. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. Huitema has nothing to disclose. Conflict of interest: Dr. Bakker has nothing to disclose. Conflict of interest: Dr. Mager has nothing to disclose. Conflict of interest: Dr. Rensing has nothing to disclose. Conflict of interest: Dr. Smits has nothing to disclose. Conflict of interest: Dr. Snijder has nothing to disclose. Conflict of interest: Dr. Grutters has nothing to disclose. Conflict of interest: Dr. Post has nothing to disclose.